"10.1371_journal.pone.0091577","plos one","2014-03-24T00:00:00Z","Frances E Lennon; Tamara Mirzapoiazova; Bolot Mambetsariev; Valeriy A Poroyko; Ravi Salgia; Jonathan Moss; Patrick A Singleton","Section of Pulmonary and Critical Care, Department of Medicine, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, United States of America; Department of Surgery, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, United States of America; Section of Hematology/Oncology, Department of Medicine, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, United States of America; Department of Anesthesia and Critical Care, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, United States of America","Conceived and designed the experiments: FEL JM RS PAS. Performed the experiments: TM BM VAP FEL. Analyzed the data: JM PAS. Contributed reagents/materials/analysis tools: PAS JM. Wrote the paper: PAS.","Methylnaltrexone was developed at the University of Chicago and licensed to Progenics Pharmaceuticals, subsequently sub-licensed to Salix Pharmaceuticals. Dr. Moss was a paid consultant for Progenics Pharmaceuticals and currently is a paid consultant for Salix Pharmaceuticals. He receives royalties through the University of Chicago. There are no patent(s) or patent applications relating to material pertinent to this article. This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials.","2014","03","Frances E Lennon","FEL",7,TRUE,4,4,2,1,TRUE,FALSE,FALSE,0,NA,FALSE
